In SLE mice, oral administration of metformin can increase nTregs, reduce Th17 cells, inhibit mTOR and signal transducer and activator of transcription 3 (STAT3) signaling, as well as decrease the severity of inflammation. This evidence concerns the gene STAT3 and systemic lupus erythematosus.